ArticleSexual medicine2026
Efficacy and safety of collagenase
Article in Sexual medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While prior studies have demonstrated that men who have sex with men (MSM) may disproportionately experience distress due to Peyronie's disease (PD), limited evidence exists regarding the outcomes of these men when treated with collagenase Aim: To investigate the outcomes of MSM undergoing CCH injections for PD. Methods: A retrospective analysis was performed for 790 patients undergoing CCH injections for PD at 5 academic centers within the United States, including data pertaining to demographic information, sexual orientation, penile curvature characteristics, treatment characteristics, and treatment-related outcomes. Outcomes: The impact of sexual orientation on treatment-related satisfaction, efficacy, and complication rates. Results: Of the 399 patients meeting the final inclusion criteria, 6.51% ( Clinical Implications: An improved understanding of the outcomes of MSM receiving CCH injections may improve counseling regarding and management of PD for a vulnerable population of patients. Strengths and Limitations: This study offers some of the first data examining outcomes for PD in MSM patients. However, the retrospective and multicohort nature of the study, as well as its small cohort size, may result in impactful bias. Conclusion: In our trial, MSM patients receiving CCH were with similar treatment efficacy, treatment satisfaction, and rates of operative complications, suggesting that CCH is an efficacious and safe treatment for MSM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.